Phase III Trial Launches to Evaluate Atezolizumab as First Postoperative Therapy for Stage I NSCLC
核心洞察
A new national phase III trial (AASI-NSCLC/A082302) will evaluate whether one year of atezolizumab after surgery can improve outcomes for stage I non-small cell lung cancer (搜索) patients.
Currently, no approved postoperative therapy exists for stage I NSCLC, and approximately 20% to 30% of patients experience disease recurrence following surgery.
The trial is led by Muhammad Furqan, M.D., at OU Health Stephenson Cancer Center (搜索) and conducted through the NCI's National Clinical Trials Network.
A national phase III clinical trial has been launched to determine whether the immunotherapy drug atezolizumab can improve outcomes for patients with stage I non-small cell lung cancer (搜索) (NSCLC) following surgical resection — a patient population that currently has no approved postoperative treatment options.
The trial, designated AASI-NSCLC (A082302), is led by Muhammad Furqan, M.D., professor of hematology-oncology at the University of Oklahoma College of Medicine and Associate Director of Clinical Research at OU Health Stephenson Cancer Center (搜索). It is being conducted through the National Cancer Institute's National Clinical Trials Network, with participation from the Alliance for Clinical Trials in Oncology, SWOG Cancer Research Network, ECOG-ACRIN Cancer Research Group, and NRG Oncology.
A Critical Unmet Need in Early-Stage Lung Cancer
Lung cancer remains the leading cause of cancer-related death among both men and women in the United States, accounting for approximately 20% of all cancer deaths. NSCLC represents about 85% of all lung cancer diagnoses. While the overall incidence of NSCLC has declined in recent years, a growing proportion of cases are being diagnosed at earlier stages — including stage I disease — largely due to increased screening and earlier detection of smaller tumors.
Surgery is the standard treatment for patients with stage I NSCLC. Following surgery, patients are monitored with routine imaging to detect recurrence. However, approximately 20% to 30% of patients experience disease recurrence, which is often no longer curable. Currently, there is no postoperative therapy for patients with stage I NSCLC removed through surgery.
"The success of immunotherapy in more advanced stages of lung cancer raises an important question: Can we improve outcomes for patients with stage I disease who currently have no approved postoperative treatment options?" Furqan said. "This trial is designed to answer that question."
Building on Immunotherapy's Track Record
Over the past decade, immunotherapy has transformed the treatment of lung cancer and significantly improved outcomes for patients with stage II, III, and IV disease. Researchers now hope to determine whether immunotherapy can also benefit patients with stage I NSCLC by reducing the risk of recurrence and potentially preventing the development of new lung cancers.
The question is particularly relevant in Oklahoma, where lung cancer incidence and mortality remain high, and ongoing efforts at OU Health Stephenson Cancer Center (搜索) and across the state are focused on improving lung cancer screening and early detection to enhance outcomes for patients.
Trial Design and Endpoints
In the randomized phase III study, participants will be assigned to receive either one year of the immunotherapy drug atezolizumab following surgery or standard surveillance alone. Investigators will evaluate whether the addition of immunotherapy improves disease-free survival and overall survival.
If successful, the trial could establish the first postoperative treatment strategy for patients with stage I NSCLC that has been surgically removed and potentially change the standard of care for thousands of patients diagnosed each year.